AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

45. (currently amended): A method for the treatment of diseases of the central nervous system (excluding those involving CNS depressant action), the cardiovascular system (excluding hypertension), the kidney, or diseases associated with abnormal adrenal gland secretions, or for the treatment of hyperglycaemia or peptic ulcer, which comprises administering an effective amount of a compound of formula II:



II

wherein W is ~~optionally substituted aryl; optionally substituted C_5-C_7 cycloalkyl;~~ CHR^1R^2 where R^1 and R^2 are independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_7 cycloalkyl and optionally substituted aryl or R^1 and R^2 are linked to form an optionally substituted C_5-C_7 cycloalkyl; ~~OR' where R' is optionally substituted aryl; optionally substituted C_3-C_7 cycloalkyl; or optionally substituted C_1-C_6 alkyl; provided that R^1 and R^2 are not both hydrogen~~;

Z is imino, ~~C_1-C_2 alkylene, CH_2NH or CH_2CH_2NH~~;

X is O ~~or S~~; and

Y is optionally substituted C_2-C_3 alkylene~~; provided that W is not OR' when Z is imino or $-CH_2NH-$;~~

or a pharmaceutically acceptable salt or ester thereof.

46. (currently amended): The method according to claim 45 wherein the disease is a disease of the central nervous system selected from the group consisting of dementia, mood disturbances, degenerative conditions and neurodegenerative diseases.

47. (currently amended): A method for the treatment of glaucoma comprising administering an effective amount of a compound of formula II



II

wherein W ~~is optionally substituted aryl; optionally substituted C_5-C_7 cycloalkyl;~~ $-CHR^1R^2$ where R^1 and R^2 are independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_7 cycloalkyl and optionally substituted aryl or R^1 and R^2 are linked to form an optionally substituted C_5-C_7 cycloalkyl; ~~OR' where R' is optionally substituted aryl;~~

~~optionally substituted C_3-C_7 cycloalkyl; or optionally substituted C_1-C_6 alkyl; provided that R^1 and R^2 are not both hydrogen;~~

Z is imino~~, C_1-C_2 alkylene, CH_2NH or CH_2CH_2NH~~;

X is O ~~or S~~; and

Y is optionally substituted C_2-C_3 alkylene; ~~provided that W is not OR' when Z is imino or CH_2NH;~~ and

with the further provisos that

a) when Y is CH_2CH_2, X is O and Z is imino then

(i) if W is CHR^1R^2 and R^1 is H then R^2 is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethyl phenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6-dimethylphenyl; and

(ii) if W is CHR^1R^2 and R^1 is CH_3 or cyclopropyl then R^2 is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and

b) when Y is $(CH_2)_{2-4}$, X is O ~~or S~~, Z is imino and W is CHR^1R^2, then

(i) if R^1 is CF_3, CF_2CF_3 or $CF_2CF_2CF_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and

(ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.

48. (currently amended): A method for the treatment of diseases of the central nervous system, cardiovascular system, or the kidney, or for the treatment of diseases associated with abnormal adrenal gland secretions, or in the treatment of hyperglycaemia, glaucoma, peptic ulcer or to produce analgesia which comprises administering an effective amount of a compound of formula II



II

wherein W is ~~optionally substituted aryl; optionally substituted C_5-C_7 cycloalkyl;~~ CHR^1R^2 where R^1 and R^2 are independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_7 cycloalkyl and optionally substituted aryl or R^1 and R^2 are linked to form an optionally substituted C_5-C_7 cycloalkyl; ~~OR' where R' is optionally substituted aryl; optionally substituted C_3-C_7 cycloalkyl; or optionally substituted C_1-C_6 alkyl; provided that R^1 and R^2 are not both hydrogen;~~

Z is imino~~, C_1-C_2 alkylene, CH_2NH or CH_2CH_2NH~~;

X is O ~~or S~~; and

Y is optionally substituted C_2-C_3 alkylene; ~~provided that W is not OR' when Z is imino or CH_2NH;~~ and

with the further provisos that

a) when Y is CH_2CH_2, X is O and Z is imino then

(i) W is not unsubstituted or 2-mono-, 2,2-di, 2,5-di, 2,6-di or 2,4,6-tri C_{1-3} alkyl substituted cyclohexyl or 2-mono- or 2,5,-di C_{1-3} alkyl substituted cyclopentyl or 2-C_{1-3} alkyl substituted cycloheptyl; and

(ii) if W is CHR^1R^2 and R^1 is H then R^2 is not selected from phenyl; phenyl substituted with methoxy, Br. Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethylphenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6 dimethylphenyl; and

(iii) if W is CHR^1R^2 and R^1 is CH_3 or cyclopropyl then R^1 is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and

b) when Y is $(CH_2)_{2-4}$, X is O ~~or S~~, Z is imino and W is CHR^1R^2, then

(i) if R^1 is CF_3, CF_2CF_3 or $CF_2CF_2CF_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and

(ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.

49. (previously presented): The method according to claim 46, wherein the disease is a degenerative condition selected from the group consisting of stroke, aging, ischemia, and CNS trauma.

50. (previously presented): The method according to claim 46, wherein the disease is a neurodegenerative disease selected from the group consisting of Alzheimer's disease and Parkinson's disease.

51. (currently amended): The method according to claim 45, 47 or 48, wherein W is ~~aryl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_1-C_6 alkynyl or aryloxy); C_5-C_6 cycloalkyl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl or aryloxy);~~ CHR^1R^2 where R^1 and R^2 are independently selected from hydrogen, C_1-C_6 alkyl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl or aryloxy), C_3-C_6 cycloalkyl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl or aryloxy) and aryl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl or aryloxy)~~; OR' where R' is aryl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl or aryloxy); C_3-C_6 cycloalkyl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl or aryloxy); or C_1-C_6 alkyl (optionally substituted with hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl or aryloxy).

52. (currently amended): The method according to claim 45, 47 or 48, wherein W is ~~phenyl, cyclohexyl or naphthyl, each of which may be optionally substituted with one to three substituents selected from hydroxy, methoxy, ethoxy, benzyloxy, NO_2, NH_2, halogen, methyl and ethyl; or~~ CHR^1R^2 where R^1 and R^2 are independently selected from phenyl, naphthyl, cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, methyl, ethyl, propyl and butyl, each of which may be optionally substituted with hydroxy, methoxy, ethoxy, benzyloxy, NO_2, NH_2, halogen, methyl and ethyl.

53. (canceled).

54. (previously presented): The method according to claim 45, 47 or 48, wherein Y is C_2-C_3 alkylene optionally substituted with C_1-C_4 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkanoyloxy or C_1-C_6 alkyloxycarbonyl, or with two substituents which join together to form a 5-6 membered carbocyclic or heterocyclic ring.

55. (previously presented): The method according to claim 54, wherein Y is unsubstituted C_2-C_4 alkylene.

56. (previously presented): The method according to claim 54, wherein Y is ethylene.

57. (currently amended): The method according to claim 45, 47 or 48, wherein the compound of formula II is a compound of formula III:



III

wherein R^3, R^4, R^5 and R^6 are independently selected from hydrogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl and aryloxy;

Z is imino~~, C_1-C_2 alkylene, or CH_2CH_2NH~~;

R^7 and R^8 are independently selected from hydrogen, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkanoyloxy and C_1-C_6 alkyloxycarbonyl, or R^7 and R^8 may together form a 5 or 6 membered aromatic or non-aromatic carbocyclic or heterocyclic ring;

a compound of formula IV:



IV

where R^3, R^4, R^7, R^8 and Z are as defined in relation to formula III;

a compound of formula V:



where R^3, R^4, R^7 and Z are as defined in relation to formula III, and R^9 is C_1-C_4 alkyl or C_1-C_4 alkoxy;

a compound of formula VI:



where R^7, R^8 and Z are as defined in relation to formula III and R^{10} and R^{11} are independently selected from hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2, NH_2, C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_3-C_6 alkenyl, C_2-C_6 alkynyl and aryloxy; or

a compound of formula VII:



where R^7, R^8 and Z are as defined in relation to formula III and R^{12} is hydrogen optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_7 cycloalkyl or optionally substituted aryl; ~~a~~

~~compound of formula VIII:~~



~~where φ is optionally substituted aryl and R^7, R^8 and Z are defined in relation to formula III;~~

~~a compound of formula IX:~~



~~where R^7, R^8 and Z and φ are as defined in relation to formula VIII; or~~

~~a compound of formula X:~~



~~where R^7, R^8, R^{12} and Z are as defined in relation to formula VII and φ is as defined in relation to formula IX~~.